FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 206 filers reported holding FATE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $507,000 | +48.7% | 5,837 | +41.1% | 0.02% | +66.7% |
Q1 2021 | $341,000 | -9.3% | 4,137 | 0.0% | 0.01% | -10.0% |
Q4 2020 | $376,000 | -47.8% | 4,137 | -77.0% | 0.01% | -71.4% |
Q3 2020 | $720,000 | +35.8% | 18,021 | +16.7% | 0.04% | +20.7% |
Q2 2020 | $530,000 | – | 15,448 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |